crystallizing into NPLs in coming quarters. However, the provisioning expense of 14.3bn (7.7bn in 4QFY21) has translated into substantial improvement in PCR to 76.3%. Moreover, the covid provisioning (6.5bn) stood 114bps of net advances. The Bank witnessed 19bps improvement in NIMs to 4.36% because of healthy YoA (11.6% v/s 11.2% sequentially) and reduction in CoF (5.27% v/s 5.45% sequentially). As expected, the bank reported a credit de-growth of 3.6 % sequentially. We estimate the growth to remain tepid for FY22E but adequate provision is likely to give comfort to the balance sheet. Factoring the in-expensive valuation (0.9x PBV) and a stable...